Antonio J. Muñoz García

Antonio J. Muñoz García

Auto-generated profile, based on publicly available information

Antonio J. Muñoz García

University Hospital Virgen de la Victoria, Department of Cardiology, Malaga, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2014 in Circulation
Verified
Journal Article
Closed access
MUMarina Urena
Marina Urena
JWJohn G. Webb
John G. Webb
CTCorrado Tamburino
Corrado Tamburino
AMAntonio J. Muñoz-García
Antonio J. Muñoz-García
ACAsim Cheema
Asim Cheema
JRJosep Rodés-Cabau
Josep Rodés-Cabau
Background—: Very few data exist on the clinical impact of permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation. The objective of this study was to assess the impact of PPI after transcatheter aortic valve implantation on late outcomes in a large cohort of patients. Methods and Results—: A total of 1556 consecutive patients without prior PPI undergoing transcatheter aortic valve implantation were included. Of them, 239 patients (15.4%) required a PPI within the first 30 days after transcatheter aortic valve implantation. At a mean follow-up of 22±17 months, no association was observed between the need for 30-day PPI and all-cause mortality (hazard ratio, 0.98; 95% confidence interval, 0.74–1.30; P =0.871), cardiovascular mortality (hazard ratio, 0.81; 95% confidence interval, 0.56–1.17; P =0.270), and all-cause mortality or rehospitalization for heart failure (hazard ratio, 1.00; 95% confidence interval, 0.77–1.30; P =0.980). A lower rate of unexpected (sudden or unknown) death was observed in patients with PPI (hazard ratio, 0.31; 95% confidence interval, 0.11–0.85; P =0.023). Patients with new PPI showed a poorer evolution of left ventricular ejection fraction over time ( P =0.017), and new PPI was an independent predictor of left ventricular ejection fraction decrease at the 6- to 12-month follow-up (estimated coefficient, −2.26; 95% confidence interval, −4.07 to −0.44; P =0.013; R 2 =0.121). Conclusions—: The need for PPI was a frequent complication of transcatheter aortic valve implantation, but it was not associated with any increase in overall or cardiovascular death or rehospitalization for heart failure after a mean follow-up of ≈2 years. Indeed, 30-day PPI was a protective factor for the occurrence of unexpected (sudden or unknown) death. However, new PPI did have a negative effect on left ventricular function over time.

5 May 2015 in Circulation
Verified
Journal Article
Closed access
IAIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
DMDavid Messika-Zeitoun
David Messika-Zeitoun
HEHelene Eltchaninoff
Helene Eltchaninoff
SKSamir Kapadia
Samir Kapadia
SLStamatios Lerakis
Stamatios Lerakis
JRJosep Rodés-Cabau
Josep Rodés-Cabau
Background—: We aimed to determine the incidence, predictors, clinical characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). Methods and Results—: This multicenter registry included 53 patients (mean age, 79±8 years; men, 57%) who suffered IE after TAVI of 7944 patients after a mean follow-up of 1.1±1.2 years (incidence, 0.67%, 0.50% within the first year after TAVI). Mean time from TAVI was 6 months (interquartile range, 1–14 months). Orotracheal intubation (hazard ratio, 3.87; 95% confidence interval, 1.55–9.64; P =0.004) and the self-expandable CoreValve system (hazard ratio, 3.12; 95% confidence interval, 1.37–7.14; P =0.007) were associated with IE (multivariate analysis including 3067 patients with individual data). The most frequent causal microorganisms were coagulase-negative staphylococci (24%), followed by Staphylococcus aureus (21%) and enterococci (21%). Vegetations were present in 77% of patients (transcatheter valve leaflets, 39%; stent frame, 17%; mitral valve, 21%). At least 1 complication of IE occurred in 87% of patients (heart failure in 68%). However, only 11% of patients underwent valve intervention (valve explantation and valve-in-valve procedure in 4 and 2 patients, respectively). The mortality rate in hospital was 47.2% and increased to 66% at the 1-year follow-up. IE complications such as heart failure ( P =0.037) and septic shock ( P =0.002) were associated with increased in-hospital mortality. Conclusions—: The incidence of IE at 1 year after TAVI was 0.50%, and the risk increased with the use of orotracheal intubation and a self-expandable valve system. Staphylococci and enterococci were the most common agents. Although most patients presented at least 1 complication of IE, valve intervention was performed in a minority of patients, and nearly half of the patients died during the hospitalization period.

1 February 2016 in JACC
Verified
Journal Article
Closed access
MTMaria Del Trigo
Maria Del Trigo
AMAntonio J. Muñoz-Garcia
Antonio J. Muñoz-Garcia
HWHarindra C. Wijeysundera
Harindra C. Wijeysundera
LNLuis Nombela-Franco
Luis Nombela-Franco
ACAsim N. Cheema
Asim N. Cheema
JRJosep Rodés-Cabau
Josep Rodés-Cabau

1 February 2015 in JACC
Verified
Journal Article
Closed access
MUMarina Urena
Marina Urena
JWJohn G. Webb
John G. Webb
HEHelene Eltchaninoff
Helene Eltchaninoff
AMAntonio J. Muñoz-García
Antonio J. Muñoz-García
CBClaire Bouleti
Claire Bouleti
JRJosep Rodés-Cabau
Josep Rodés-Cabau

5 May 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
RARicardo Allende
Ricardo Allende
JWJohn G. Webb
John G. Webb
AMAntonio J. Munoz-Garcia
Antonio J. Munoz-Garcia
PJPeter de Jaegere
Peter de Jaegere
CTCorrado Tamburino
Corrado Tamburino
JRJosep Rodés-Cabau
Josep Rodés-Cabau
The aim of this study was to determine the effects of advanced chronic kidney disease (CKD) on early and late outcomes after transcatheter aortic valve implantation (TAVI), and to evaluate the predictive factors of poorer outcomes in such patients. This was a multicentre study including a total of 2075 consecutive patients who had undergone TAVI. Patients were grouped according the estimated glomerular filtration rate as follows: CKD stage 1-2 (≥60 mL/min/1.73 m2; n = 950), stage 3 (30–59 mL/min/1.73 m2; n = 924), stage 4 (15–29 mL/min/1.73 m2; n = 134) and stage 5 (<15 mL/min/1.73 m² or dialysis; n = 67). Clinical outcomes were evaluated at 30-days and at follow-up (median of 15 [6–29] months) and defined according to the VARC criteria. Advanced CKD (stage 4–5) was an independent predictor of 30-day major/life-threatening bleeding (P = 0.001) and mortality (P = 0.027), and late overall, cardiovascular and non-cardiovascular mortality (P < 0.01 for all). Pre-existing atrial fibrillation (HR: 2.29, 95% CI: 1.47–3.58, P = 0.001) and dialysis therapy (HR: 1.86, 95% CI: 1.17–2.97, P = 0.009) were the predictors of mortality in advanced CKD patients, with a mortality rate as high as 71% at 1-year follow-up in those patients with these 2 factors. Advanced CKD patients who had survived at 1-year follow-up exhibited both a significant improvement in NYHA class (P < 0.001) and no deterioration in valve hemodynamics (P = NS for changes in mean gradient and valve area over time). Advanced CKD was associated with a higher rate of early and late mortality and bleeding events following TAVI, with AF and dialysis therapy determining a higher risk in these patients. The mortality rate of patients with both factors was unacceptably high and this should be taken into account in the clinical decision-making process in this challenging group of patients.

1 August 2016 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
CCCarlos Cortés
Carlos Cortés
Ignacio J. Amat-SantosIgnacio J. Amat-Santos
Ignacio J. Amat-Santos
LNLuis Nombela-Franco
Luis Nombela-Franco
AMAntonio J. Muñoz-Garcia
Antonio J. Muñoz-Garcia
EGEnrique Gutiérrez-Ibañes
Enrique Gutiérrez-Ibañes
JCJosé Alberto San Román Calvar
José Alberto San Román Calvar